Why the study?
Proton pump inhibitors and ceftriaxone carry concerns regarding QT prolongation, ventricular arrhythmias, and cardiac arrest, but their combined cardiovascular risks remain underexplored.
Does the combination of ceftriaxone and lansoprazole increase the risk of QT prolongation, ventricular arrhythmias, and cardiac arrest compared to other PPIs in patients receiving ceftriaxone?
Does the combination of ceftriaxone and lansoprazole increase the risk of QT prolongation, ventricular arrhythmias, and cardiac arrest compared to other PPIs in patients receiving ceftriaxone?
The combination of ceftriaxone and lansoprazole is associated with a significantly increased risk of QT prolongation, ventricular arrhythmias, and cardiac arrest compared to other PPI combinations.
Answers are grounded in this paper and cite their sources.
Supports considering alternative agents or ECG monitoring; leaves open a causal interaction pending higher-quality evidence.
BACKGROUND Proton pump inhibitors (PPIs) and ceftriaxone are frequently used for gastrointestinal and infection treatments. However, concerns about cardiovascular risks, including QT prolongation, ventricular arrhythmias, and cardiac arrest (QVC events), have emerged, yet their combined effects remain underexplored. OBJECTIVE To verify the drug interaction between ceftriaxone and lansoprazole that may increase the risk of QVC events, and to investigate the existence of similar risks with the combinations of other PPIs. METHODS We analyzed adverse event reports from the FAERS and CVAR databases between 2004 Q1 and 2024 Q3. Disproportionality analysis and drug-drug interaction (DDI) analysis were employed to explore the relationships between different drug combinations and QVC events. Additionally, relevant data were extracted from the MIMIC-IV database. Multivariate Cox regression and competing risks models evaluated the QVC events, with 1:2 propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) utilized to address confounding factors. RESULTS The combination of ceftriaxone and lansoprazole showed a significant association with the QVC events, revealing notable DDIs (e.g., in FAERS, Ω025=0.54). To validate these findings, a cohort of 5,594 patients receiving ceftriaxone combined with PPIs from the MIMIC-IV database was analyzed using Cox proportional-hazards and competing risk models, with propensity score matching and inverse probability weighting for covariate adjustment. Analyses corroborated the initial findings (lansoprazole vs other PPIs, multivariable HR=1.30; 95% CI: 1.10–1.54), with the risk associated with the three PPI combinations ranked as follows: lansoprazole > pantoprazole > omeprazole. CONCLUSIONS The study concludes that the ceftriaxone-lansoprazole combination increases QVC event risks, and there is also a certain level of risk associated with the use of other PPIs in combination.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: